善胃方对气阴两虚型胃癌前期病变EGF及EGFR的影响

Effect of Shanwei Presciption on EGF and EGFR in precancerous stage of stomach cancer due to both qi and yin deficiency

关键词:  善胃方  胃癌前期病变  EGF  EGFR  益气养阴

Key words:  Shanwei Prescription  stomach cancer in precancerous stage  EGF  EGFR  tonifying the qi and yin

摘要:

[目的]观察中药善胃方对胃癌前期病变的治疗效果,并观察表皮生长因子(EGF)及表皮生长因子受体(EGFR)在治疗前后的表达情况。[方法]将内镜和病理确诊为慢性萎缩性胃炎伴胃黏膜异型增生且符合中医气阴两虚型的患者60例,随机分为治疗组30例,予善胃方;对照组30例,予猴头菌片,两组均用药6个月。[结果]1)治疗组患者治疗前后症状缓解总有效率为90.00%;对照组患者治疗前后症状缓解总有效率为55.67%,P<0.01;2)病理改变:中药治疗后多数患者病理改善,萎缩、肠化、不典型增生均有改善;而对照组萎缩、肠化、不典型增生改善不明显,中药组明显优于对照组,P<0.05;3)中药治疗组治疗前后EGF、EGFR表达显著降低,与对照组相比两者有显著性差异,P<0.05。[结论]中药善胃方对胃癌前期病变有一定的治疗作用,并通过适当降低EGF及EGFR表达水平而在一定程度上使胃黏膜病理逆转。

Abstract:

[Objective] To observe the therapeutic effect of Shanwei Prescription on stomach cancer in precancerous stage and the expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) before and after the treatment. [Methods] Sixty cases with chronic atrophic gastritis complicated by gastric mucosa hyperplasia and diagnosed by endoscope and pathologic examination were randomly divided into treatment group and control group. All the patients referable to the qi and yin deficiency type in TCM, 30 cases each group, were given Shanwei Prescription or heriacium tablet respectively for 6 months. [Result] 1) The total effective rate for symptoms improvement was 90.0%after treatment in treatment group, while the control group was 55.67% (P<0.01).2) Improvement of pathologic changes was observed in most patients after the treatment with Chinese herbs. The atrophy,intestinal metaplasia and atypical hyperplasia were improved.There was a significant difference between these two groups (P<0.05). 3) The marked decreasing expression of EGF and EGFR was observed after treatment in Chinese herbs group with significant difference when compared with the control group (P<0.05).[Conclusion] Shanwei Prescription has certain therapeutic effect on stomach cancer in precancerous stages and is able to reverse some pathologic changes of gastric mucosa to a certain degree by appropriately decreasing the expression of EGF and EGFR.